MX2021004462A - Inmunomoduladores en combinacion con radioterapia para el cancer de pancreas avanzado. - Google Patents

Inmunomoduladores en combinacion con radioterapia para el cancer de pancreas avanzado.

Info

Publication number
MX2021004462A
MX2021004462A MX2021004462A MX2021004462A MX2021004462A MX 2021004462 A MX2021004462 A MX 2021004462A MX 2021004462 A MX2021004462 A MX 2021004462A MX 2021004462 A MX2021004462 A MX 2021004462A MX 2021004462 A MX2021004462 A MX 2021004462A
Authority
MX
Mexico
Prior art keywords
combination
pancreatic cancer
radiation treatment
immune modulators
advanced pancreatic
Prior art date
Application number
MX2021004462A
Other languages
English (en)
Inventor
Scott Andrew Gerber
Dominick Auci
Original Assignee
Univ Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rochester filed Critical Univ Rochester
Publication of MX2021004462A publication Critical patent/MX2021004462A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1048—Monitoring, verifying, controlling systems and methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Abstract

La invención proporciona métodos para tratar el cáncer de páncreas metastásico o irresecable mediante la administración de una combinación de un inmunomodulador y radioterapia.
MX2021004462A 2018-10-19 2019-10-18 Inmunomoduladores en combinacion con radioterapia para el cancer de pancreas avanzado. MX2021004462A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862747830P 2018-10-19 2018-10-19
PCT/US2019/056927 WO2020081929A1 (en) 2018-10-19 2019-10-18 Immune modulators in combination with radiation treatment for advanced pancreatic cancer

Publications (1)

Publication Number Publication Date
MX2021004462A true MX2021004462A (es) 2021-06-04

Family

ID=68468844

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004462A MX2021004462A (es) 2018-10-19 2019-10-18 Inmunomoduladores en combinacion con radioterapia para el cancer de pancreas avanzado.

Country Status (7)

Country Link
US (1) US20210387020A1 (es)
EP (1) EP3866832A1 (es)
JP (1) JP7450944B2 (es)
AU (1) AU2019362029A1 (es)
CA (1) CA3115677A1 (es)
MX (1) MX2021004462A (es)
WO (1) WO2020081929A1 (es)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4861581A (en) 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5019368A (en) 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
WO1990005785A1 (en) 1988-11-18 1990-05-31 The Regents Of The University Of California Method for site-specifically incorporating unnatural amino acids into proteins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US6143211A (en) 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US6103489A (en) 1997-03-21 2000-08-15 University Of Hawaii Cell-free protein synthesis system with protein translocation and processing
US6051428A (en) * 1997-03-21 2000-04-18 Sloan-Kettering Institute For Cancer Research Rapid production of autologous tumor vaccines
EP1087785A2 (en) * 1998-06-15 2001-04-04 Arch Development Corporation Combination of radiotherapy and anti-angiogenic factors
AU1086501A (en) 1999-10-15 2001-04-30 Carnegie Institution Of Washington Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
JP2003530836A (ja) * 2000-04-12 2003-10-21 ユニバーシティー オブ ロチェスター 標的化ワクチン送達システム
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
ATE458500T1 (de) * 2003-11-14 2010-03-15 Genvec Inc Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
EP2804620A4 (en) * 2012-01-18 2016-04-13 Neumedicines Inc IL-12 FOR RADIATION PROTECTION AND RADIATION-RELATED TOXICITY WEAKENING
CA2929277C (en) * 2013-11-01 2018-01-16 Yale University Delivery vehicles comprising il-2 and losartan
EP3179985A1 (en) 2014-08-14 2017-06-21 Brown University Compositions for stabilizing and delivering proteins
NZ738527A (en) * 2015-05-28 2022-07-01 Nanobiotix Nanoparticles for use as a therapeutic vaccine

Also Published As

Publication number Publication date
EP3866832A1 (en) 2021-08-25
JP7450944B2 (ja) 2024-03-18
CA3115677A1 (en) 2020-04-23
JP2022505408A (ja) 2022-01-14
WO2020081929A1 (en) 2020-04-23
AU2019362029A1 (en) 2021-04-01
US20210387020A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
MX2022008868A (es) Tratamiento del cancer con tg02.
NZ750974A (en) Antibody and checkpoint inhibitor combination therapy
MX2019012532A (es) Moduladores de k-ras.
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
MX2021000745A (es) Composiciones anti-cd112r y metodos.
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
MX2019003938A (es) Compuestos espirociclicos.
MX364705B (es) Sistemas y metodos para tratar el cancer y/o aumentar la funcion de organos.
MX2021009899A (es) Administracion y dosificacion de diaminofenotiazinas.
MX2019002925A (es) Modulacion inmune con agonistas de tlr9 para el tratamiento del cancer.
EP3876965A4 (en) MULTI-THERAPIES BASED ON MICRO-ORGANISMS AND IMMUNE MODULATORS FOR USE IN THE TREATMENT OF CANCER
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
MX2021003903A (es) Terapia combinada para el melanoma.
MX2020006297A (es) Variantes de cd19.
MX2019003722A (es) Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan.
MX2017009246A (es) Farmaco de combinacion.
IL272669A (en) Combination therapy with a combination of anti-CSF1R and anti-PD-1 antibodies for pancreatic cancer
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
MX2018010847A (es) Terapia combinada mediante el uso de un conjugado de anticuerpo-farmaco de liv1 (liv1-adc) y agente quimioterapeutico.
MX2020012475A (es) Metodo para tratar el trastorno depresivo mayor.
MX2019003314A (es) Metodos de tratamiento de la elevacion de dominio 3 de inmunoglobulina de celula t y mucina (tim-3).
JOP20210144A1 (ar) أجسام مضادة للبيريوستين واستخداماتها
MX2021004462A (es) Inmunomoduladores en combinacion con radioterapia para el cancer de pancreas avanzado.
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.